Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2012.  Palatin reported a net loss of $1.7 million, or $(0.02) per basic and diluted share, for the quarter ended December 31, 2012, compared to a net loss of $2.6 million, or $(0.08) per basic and diluted share, for the same period in 2011. 

The decrease in net loss for the quarter ended December 31, 2012, compared to the same period last fiscal year, is primarily attributable to an increase in net proceeds from the sale of New Jersey state net operating loss carryforwards, which resulted in the recognition of $1.8 million and $1.1 million, respectively, in tax benefits for the three months ended December 31, 2012 and 2011, and secondarily to a decrease in operating expenses for the periods presented.

REVENUE
Revenues, which consisted of contract revenue pursuant to the collaboration agreement with AstraZeneca, were $6,555 for the quarter ended December 31, 2012 compared to $11,492 for the quarter ended December 31, 2011.

COSTS AND EXPENSES
Total operating expenses for the quarter ended December 31, 2012 were $3.4 million compared to $3.7 million for the comparable quarter of 2011.  The decrease in operating expenses for the quarter was primarily due to lower costs related to Palatin's Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD), which Palatin reported positive top-line results on November 8, 2012.

CASH POSITION
Palatin's cash and cash equivalents were $32.9 million as of December 31, 2012, compared to $3.8 million at June 30, 2012, with current liabilities of $2.0 million as of December 31, 2012 compared to $3.5 million as of June 30, 2012
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... bromine market in Asia-Pacific with analysis and forecast ... the Asia Pacific Bromine Market report, to get ... also provides a glimpse of the segmentation in ... various tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report ... and forecast of revenue. The Orthopedic braces and support systems ... million by 2018, at a developing CAGR of 4.4% from ... Asian Orthopedic braces and support systems market, to get an ... glimpse of the segmentation of orthopedic braces and support systems ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... Silence Therapeutics plc (London AIM:,SLN), a leading ... reasons, Jeffery Vick has resigned as Group CEO ... has appointed Iain Ross, currently Non-Executive,Chairman, full time ... Cook, a Non-Executive Director of the Company has ...
... Ltd. (Nasdaq: XTLB ; TASE: XTL) announces ... Meeting ("EGM") scheduled,for today were adjourned and postponed ... pm Israel time, respectively., ABOUT XTL BIOPHARMACEUTICALS ... in the development of,therapeutics for the treatment of ...
... Channel Targets for ... at 10:10, CLEVELAND, July 17 ChanTest,s role ... and services for,drug-discovery and development applications will be featured ... The Cleveland-based,company will be exhibiting in booth 839 its ...
Cached Biology Technology:Organizational Changes at Silence Therapeutics 2Organizational Changes at Silence Therapeutics 3ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839 2ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839 3
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... ITHACA, N.Y. – Scientists have sequenced the house fly ... as one might expect from an insect that thrives ... research, published Oct. 14 in the journal Genome ... and biology and of how flies quickly adapt to ... , Adult house flies (Musca domestica) carry and transmit ...
(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Tech Wake Forest University,s School of Biomedical Engineering and ... and Simulation Award for 2008. The Office of ... of the Army presented the award for research that could ... with facial injury. The center was selected from ...
... up to half of a person,s body mass consisting ... which include those found in the limbs can ... of Illinois kinesiology and community health professor Kimberly Huey, ... Vitamin E may be associated with reduced expression of ...
... as of January 2009. The official journal of the ... is respected internationally for the publication of basic and ... areas relevant to fisheries science. Published in ... includes original and review articles covering a wide array ...
Cached Biology News:New dummy design and development wins US Department of Defense award 2Vitamin E shows possible promise in easing chronic inflammation 2Vitamin E shows possible promise in easing chronic inflammation 3
... RNA sequences from high throughput synthesis are new ... LC Sciences. These products provide a large number ... sequences delivered in a microtube as a mixture ... verified RNA sequence. This is a custom product ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... The gold standard for automated ... of bioanalytical applications • Based on ... • Automated accessories designed for bioresearch ... light • Versatility, reliability and ease-of-use ...
... Arrays contain 60 rabbit tissue samples arrayed on ... unstained slides and 1 hematoxylin and eosin (H&E) ... 15 different tissues from 4 rabbit organisms, for ... Each tissue sample (or core) is 1.5 mm ...
Biology Products: